Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Analysts at BTIG Research

Investment analysts at BTIG Research initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) in a report released on Tuesday, Marketbeat Ratings reports. The firm set a "buy" rating and a $60.00 price target on the stock. BTIG Research's target price indicates a potential upside of 33.19% from the stock's previous close.

Several other brokerages have also issued reports on KYMR. Truist Financial reaffirmed a "buy" rating and set a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. BMO Capital Markets started coverage on shares of Kymera Therapeutics in a research note on Friday. They set a "market perform" rating and a $55.00 target price on the stock. UBS Group dropped their price target on Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a research note on Monday, November 4th. Stephens began coverage on Kymera Therapeutics in a research report on Monday, November 18th. They set an "overweight" rating and a $65.00 price objective on the stock. Finally, Oppenheimer increased their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Friday, September 27th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $53.88.

Kymera Therapeutics Trading Up 3.2 %

NASDAQ KYMR traded up $1.40 on Tuesday, hitting $45.05. 502,682 shares of the company's stock were exchanged, compared to its average volume of 581,804. The stock has a 50-day moving average of $46.32 and a 200-day moving average of $42.71. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -18.88 and a beta of 2.16. Kymera Therapeutics has a 52 week low of $21.20 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same period in the prior year, the company earned ($0.90) EPS. Kymera Therapeutics's revenue for the quarter was down 20.9% on a year-over-year basis. As a group, analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Activity

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.82% of the stock is owned by company insiders.

Institutional Trading of Kymera Therapeutics

Large investors have recently modified their holdings of the stock. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics during the 3rd quarter valued at $61,000. Quarry LP bought a new stake in Kymera Therapeutics in the third quarter valued at $95,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after purchasing an additional 504 shares during the period. Comerica Bank boosted its position in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company's stock worth $134,000 after purchasing an additional 400 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at about $139,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.